Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: LMNA

Summary for LMNA

Gene information	Gene symbol	LMNA
	Ensembl ID	ENSG00000160789
	Entrez ID	4000
	Gene name	lamin A/C
	Synonyms	CMD1A\|HGPS\|LGMD1B\|LMN1\|LMNL1\|MADA\|PRO1
	Gene type	protein_coding
	UniProtAcc	P02545

Top

Dataset with differentially expressed gene: LMNA

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.446223	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.865601	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.516085	7.61e-26
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.62632	1.06e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.684031	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.295436	1.37e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.73407	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.669359	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.519746	1.26e-44
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Physiology B cells	-0.896068	1.30e-03
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.32938	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.306111	2.80e-45
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.847639	5.35e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.57647	4.47e-20
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.260325	7.81e-41
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.604371	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.430851	1.37e-31
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.714251	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.785243	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.74553	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.19651	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.606988	9.43e-15
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.606635	1.13e-40
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.425815	2.32e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.451578	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.52879	6.19e-36
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.78733	2.29e-35
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.478803	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.258911	7.22e-11
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.373825	3.20e-09
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.423782	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.667711	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.33668	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-1.62652	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.403338	4.48e-06
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.28239	4.50e-14
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.501476	9.59e-31
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.762039	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.460481	2.98e-08
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.343159	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.702646	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-1.12088	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.830271	0.00e+00

Top

Expression of LMNA in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to LMNA

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
LMNA	Epigenetic Alteration of DNA, RNA or Protein

Page: 1

Top

MicroRNAs (miRNA) regulating LMNA

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
LMNA	hsa-miR-548aa	99.0715	NM_170707
LMNA	hsa-miR-548t-3p	99.0715	NM_170707
LMNA	hsa-miR-548ap-3p	99.0715	NM_170707
LMNA	hsa-miR-6825-5p	96.6472	NM_001257374
LMNA	hsa-miR-6815-3p	96.1704	NM_170707
LMNA	hsa-miR-3163	91.9828	NM_170707
LMNA	hsa-miR-3714	91.3837	NM_170707
LMNA	hsa-miR-9983-3p	90.6655	NM_170707
LMNA	hsa-miR-129-5p	88.7975	NM_170707
LMNA	hsa-miR-6510-5p	86.1203	NM_170707
LMNA	hsa-miR-9-5p	85.9639	NM_170707
LMNA	hsa-miR-6885-3p	84.0428	NM_170707
LMNA	hsa-miR-942-5p	82.7464	NM_170707
LMNA	hsa-miR-6715b-5p	82.5482	NM_170707
LMNA	hsa-miR-4269	82.5482	NM_170707
LMNA	hsa-miR-6819-3p	81.3447	NM_170707
LMNA	hsa-miR-6877-3p	81.3447	NM_170707

Page: 1

Top

Motifs and transcription factors (TFs) regulating LMNA

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
LMNA	metacluster_72.11	ZNF430 (directAnnotation).
LMNA	taipale_cyt_meth__CDX2_NRTCGTAAANNN_eDBD_meth	CDX2 (directAnnotation).
LMNA	taipale_tf_pairs__FLI1_CEBPD_RNCGGANNTTGCGCAAN_CAP	CEBPD; FLI1 (directAnnotation).
LMNA	transfac_pro__M06129	GLI4 (directAnnotation).
LMNA	transfac_pro__M05668	ZNF154 (directAnnotation).
LMNA	transfac_pro__M01239	RELA (directAnnotation).
LMNA	transfac_pro__M05908	ZNF319 (inferredBy_Orthology).
LMNA	tfdimers__MD00029	IKZF2; NKX3-2 (directAnnotation).
LMNA	transfac_pro__M06388	ZNF677 (directAnnotation).
LMNA	tfdimers__MD00370	YY1; ZNF384 (directAnnotation).
LMNA	transfac_pro__M05831	ZNF880 (directAnnotation).
LMNA	metacluster_74.23	HNF1B (inferredBy_Orthology).
LMNA	tfdimers__MD00269	CRX; PBX1 (directAnnotation).
LMNA	metacluster_74.5	HNF1B (directAnnotation).
LMNA	metacluster_26.4	CDC5L; CDC5L; CDC5L; ZNF580; ZNF580 (directAnnotation).
LMNA	tfdimers__MD00561	CRX (directAnnotation).
LMNA	swissregulon__hs__ELF2	ELF2 (directAnnotation).
LMNA	taipale_tf_pairs__ETV2_TEF_RSCGGAWNTTRCGYAAN_CAP	ETV2; TEF (directAnnotation).
LMNA	jaspar__MA1933.1	SREBF2 (directAnnotation).
LMNA	swissregulon__hs__ETV6	ETV6 (directAnnotation).
LMNA	transfac_pro__M05478	ZNF202 (directAnnotation).
LMNA	transfac_pro__M06825	ZSCAN12 (directAnnotation).
LMNA	transfac_pro__M05596	ZNF143 (directAnnotation).
LMNA	tfdimers__MD00208	IRF1; LTF (directAnnotation).
LMNA	transfac_pro__M05612	ZNF189 (directAnnotation).
LMNA	metacluster_78.20	PAX7 (inferredBy_Orthology).
LMNA	kznf__ZBTB14_Schmitges2016_RCADE	ZBTB14 (directAnnotation).
LMNA	metacluster_2.9	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).
LMNA	transfac_pro__M00801	ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM (directAnnotation). ATF7-NPFF (inferredBy_Orthology).
LMNA	tfdimers__MD00143	IKZF1; MZF1 (directAnnotation).
LMNA	metacluster_22.15	BACH1 (directAnnotation).
LMNA	metacluster_22.14	BACH1 (inferredBy_Orthology).
LMNA	swissregulon__hs__RUNX2	RUNX2 (directAnnotation).
LMNA	transfac_pro__M05397	ZNF444 (directAnnotation).
LMNA	taipale_tf_pairs__TEAD4_SOX15_NACAATRNNNNNGAATGY_CAP_repr	SOX15; TEAD4 (directAnnotation).
LMNA	transfac_pro__M06797	ZNF507 (inferredBy_Orthology).
LMNA	hdpi__SSBP3	SSBP3 (directAnnotation).
LMNA	tfdimers__MD00026	IRF1; MYB (directAnnotation).
LMNA	metacluster_2.7	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).
LMNA	metacluster_178.17	ZNF775 (directAnnotation).
LMNA	metacluster_22.16	BACH2 (directAnnotation).
LMNA	transfac_pro__M05916	ZNF407 (directAnnotation).
LMNA	taipale_tf_pairs__ERF_SREBF2_NNCACGTGACMGGAARNN_CAP_repr	ERF; SREBF2 (directAnnotation).
LMNA	taipale_tf_pairs__MYBL1_TBX21_AGGTGTGNCSGTTR_CAP_repr	MYBL1; TBX21 (directAnnotation).
LMNA	kznf__ZNF584_Imbeault2017_OM_RCADE	ZNF584 (directAnnotation).
LMNA	metacluster_70.19	POU1F1 (directAnnotation).
LMNA	transfac_pro__M06493	ZNF668 (inferredBy_Orthology).
LMNA	transfac_pro__M06826	ZNF516 (inferredBy_Orthology).
LMNA	metacluster_70.23	POU3F4 (directAnnotation).
LMNA	transfac_pro__M07448	ZBED1 (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."